- Insulin resistance affects an estimated 40% of U.S. adults and makes weight loss significantly harder by promoting fat storage and increasing hunger
- GLP-1 medications (Wegovy, Zepbound) are particularly effective for insulin-resistant patients because they address both weight and glucose regulation
- Lifestyle modifications — especially reducing refined carbohydrates and increasing physical activity — can improve insulin sensitivity independent of medication
- PEAK screens for insulin resistance markers and tailors treatment plans accordingly
Insulin resistance is one of the most common and least recognized barriers to weight loss. If you have been eating well and exercising consistently but still cannot seem to lose weight — or keep losing and regaining the same pounds — your metabolism may be working against you. Understanding what insulin resistance is, how it sabotages weight loss, and which treatments actually address the root cause can change the trajectory of your health.
What is insulin resistance?
Insulin is a hormone produced by the pancreas that helps move glucose (blood sugar) from your bloodstream into your cells, where it is used for energy. When your cells become less responsive to insulin — a condition called insulin resistance — your pancreas has to produce more and more insulin to achieve the same effect. Over time, this creates a cascade of metabolic problems.
Insulin resistance exists on a spectrum. The progression typically looks like this: normal insulin sensitivity, then insulin resistance (where your body compensates by producing excess insulin), then prediabetes (where blood sugar begins to rise), and eventually type 2 diabetes (where the pancreas can no longer keep up). The critical point is that insulin resistance can be present — and causing problems — long before blood sugar becomes abnormal.
An estimated 40% of U.S. adults aged 18–44 have some degree of insulin resistance, and hormonal changes can make it even more pronounced for women over 40. It is closely linked to visceral (abdominal) fat and metabolic syndrome — a cluster of conditions including high blood pressure, elevated triglycerides, low HDL cholesterol, and increased waist circumference.
Many people confuse insulin resistance with diabetes. They are related but distinct conditions. Insulin resistance means your cells are not responding efficiently to insulin. Diabetes means your blood sugar is chronically elevated because the system has broken down further. The good news: insulin resistance can often be reversed with treatment before it progresses to diabetes.
Common signs of insulin resistance include:
- Difficulty losing weight despite consistent effort
- Fatigue after meals, especially carbohydrate-heavy meals
- Persistent sugar and carbohydrate cravings
- Abdominal fat accumulation (central obesity)
- Acanthosis nigricans — darkened skin patches, often on the neck, armpits, or groin
- Brain fog and difficulty concentrating
Why insulin resistance blocks weight loss
Understanding the mechanism helps explain why conventional diet advice often fails for insulin-resistant patients. High insulin levels actively promote fat storage (a process called lipogenesis) while simultaneously inhibiting fat breakdown (lipolysis). In other words, your body is locked in fat-storage mode — even if you are eating fewer calories.
Insulin resistance also disrupts hunger hormones. Leptin resistance — a condition where your brain does not properly receive “full” signals — frequently co-occurs with insulin resistance. The result is increased hunger, stronger cravings (especially for sugar and refined carbohydrates), and a persistent drive to eat that has nothing to do with willpower.
Insulin resistance creates a metabolic trap: excess weight worsens insulin resistance, which makes weight loss harder, which leads to more weight gain. Breaking this cycle requires more than calorie counting.
This is why calorie restriction alone often fails for insulin-resistant patients. Metabolic adaptation — the body’s tendency to reduce energy expenditure in response to reduced calorie intake — is more pronounced when insulin resistance is present. Your body fights harder to hold onto weight, and the standard “eat less, move more” advice does not address the underlying metabolic dysfunction.
If you have been told you just need to try harder, eat less, or exercise more — and it still has not worked — insulin resistance may be the reason. It is a metabolic condition with measurable biomarkers that responds to medical treatment. Recognizing this distinction is the first step toward effective intervention.
Diagnosing insulin resistance
Insulin resistance is identified through a combination of blood tests and clinical assessment. Standard blood glucose tests may appear normal even when significant insulin resistance is present — which is why specific insulin-focused testing is important.
Key diagnostic markers
- Fasting insulin levels. An insulin level above 12 µU/mL is suggestive of insulin resistance. Many conventional labs do not routinely test fasting insulin, which is one reason insulin resistance goes undiagnosed.
- HOMA-IR calculation. This uses a formula — fasting glucose multiplied by fasting insulin, divided by 405 — to estimate insulin resistance. A HOMA-IR above 2.0 is generally considered suggestive of insulin resistance.
- Fasting glucose. A level between 100–125 mg/dL falls in the prediabetes range, though insulin resistance is often present even with glucose below 100.
- HbA1c. A value between 5.7–6.4% indicates prediabetes. This measures your average blood sugar over the prior 2–3 months.
- Triglyceride-to-HDL ratio. A ratio above approximately 3.0 is commonly cited as suggestive of insulin resistance, though optimal cutoffs vary by sex and ethnicity (with lower thresholds sometimes applied for women and certain populations).
At your initial evaluation, PEAK orders a full metabolic panel that includes fasting glucose, fasting insulin, HbA1c, and a full lipid panel. This allows your clinician to identify insulin resistance and factor it into your treatment plan from day one — rather than discovering it months later when standard approaches have not worked.
Medications that help
When insulin resistance is contributing to weight difficulty, medication selection matters. Not all weight loss medications address the metabolic root cause. Here are the options most relevant to insulin-resistant patients.
GLP-1-Based Medications (Wegovy, Zepbound)
GLP-1 receptor agonists are arguably the most important class of medication for insulin-resistant patients seeking weight loss. These medications improve insulin sensitivity while producing significant weight loss — a dual mechanism that directly addresses the metabolic trap described above. Semaglutide (Wegovy) and tirzepatide (Zepbound) are the two most commonly prescribed.
Tirzepatide (Zepbound) may be particularly effective for patients with metabolic syndrome because it targets both GLP-1 and GIP receptors, offering additional metabolic benefits. Clinical trials have shown it produces greater improvements in insulin sensitivity and cardiometabolic markers compared to GLP-1–only medications.
Metformin
Metformin is the first-line medication for insulin resistance and prediabetes. It works primarily by reducing hepatic (liver) glucose production and improving cellular insulin sensitivity. Weight loss with metformin alone is modest — typically 2–3% of body weight — but its value for insulin-resistant patients goes beyond the scale. It directly improves the metabolic dysfunction driving weight gain.
Metformin is also remarkably affordable. Generic versions are usually low cost at most pharmacies, making it accessible to nearly every patient. It is frequently used in combination with dedicated weight loss medications like GLP-1s for patients with significant insulin resistance.
Phentermine
Phentermine is an effective appetite suppressant that can be useful as a short-term tool for jump-starting weight loss. However, it does not directly address insulin resistance. For insulin-resistant patients, phentermine works best when used alongside metabolic treatment (such as metformin or a GLP-1) rather than as a standalone approach. For a comparison of non-GLP-1 alternatives, see Contrave vs. phentermine.
Contrave
Contrave (naltrexone/bupropion) addresses cravings through its effects on reward pathways in the brain. While it does not directly improve insulin sensitivity, the weight loss it produces can lead to modest improvements in metabolic markers. It may be appropriate for patients whose primary barrier is food cravings and emotional eating.
Some patients benefit from combining medications — for example, metformin plus a GLP-1 receptor agonist. This combination addresses insulin resistance from multiple angles: metformin reduces hepatic glucose production while the GLP-1 improves systemic insulin sensitivity and produces significant weight loss. Your clinician will determine whether a combination approach is appropriate based on your metabolic profile.
Lifestyle strategies that improve insulin sensitivity
Medication is often necessary when insulin resistance is significant, but lifestyle modifications play a critical complementary role. The research is clear: specific dietary and exercise changes can meaningfully improve insulin sensitivity, sometimes enough to reduce or eliminate the need for medication over time.
Nutrition
Reducing refined carbohydrates and added sugars is the single most impactful dietary change for insulin-resistant patients. When you eat refined carbs, blood sugar spikes rapidly, triggering a surge of insulin — exactly the pattern that worsens insulin resistance over time. Replacing refined carbs with protein, healthy fats, and fiber slows glucose absorption and reduces insulin demand.
Mediterranean-style eating patterns have been shown in clinical research to improve insulin sensitivity independent of weight loss. The emphasis on vegetables, legumes, whole grains, olive oil, fish, and moderate protein provides a sustainable framework that most patients can maintain long-term.
Exercise
Both resistance training and aerobic exercise improve insulin sensitivity, but resistance training deserves special emphasis. Building skeletal muscle increases the number of glucose receptors available in your body — essentially creating more pathways for glucose to enter cells without requiring as much insulin. Even modest increases in muscle mass can meaningfully improve insulin sensitivity.
Aerobic exercise (walking, cycling, swimming) also improves insulin sensitivity, particularly in the 24–48 hours following a session. Consistency matters more than intensity — regular moderate activity produces better metabolic outcomes than occasional intense workouts.
Sleep
Poor sleep — fewer than 7 hours per night — has been shown to worsen insulin resistance, even in otherwise healthy individuals. Sleep deprivation increases cortisol, disrupts glucose metabolism, and amplifies hunger hormones. Optimizing sleep is a foundational piece of insulin resistance treatment that is often overlooked.
Stress management
Chronic stress elevates cortisol, which directly worsens insulin resistance by promoting hepatic glucose production and increasing visceral fat storage. Addressing stress — whether through structured practices, lifestyle adjustments, or clinical support — is not optional for patients with significant insulin resistance. It is part of the treatment.
When insulin resistance is significant, lifestyle modifications alone may not be sufficient to break the metabolic cycle. Think of it this way: medication creates the metabolic conditions that allow lifestyle changes to work. Once insulin sensitivity improves and weight begins to decrease, the lifestyle strategies become more effective and may eventually sustain results on their own.
PEAK’s approach to insulin resistance
At PEAK, insulin resistance is not an afterthought — it is a central consideration in how we evaluate and treat patients. Our approach integrates metabolic screening, evidence-based medication selection, and lifestyle coaching into a unified treatment plan.
- Metabolic screening at initial evaluation. Every patient receives full bloodwork including fasting glucose, fasting insulin, HbA1c, and a full lipid panel. This identifies insulin resistance before treatment begins, not months into an ineffective plan.
- Medication selection based on metabolic profile. If insulin resistance is present, your clinician factors this into medication selection. GLP-1 medications are prioritized for patients with significant metabolic dysfunction because they address both weight and glucose regulation simultaneously.
- Metformin as adjunct therapy. When insulin resistance is prominent, metformin is considered as an adjunct to weight loss medication. Its low cost, strong safety profile, and direct impact on insulin sensitivity make it a valuable addition to many treatment plans.
- Regular metabolic monitoring. We do not just track your weight. Metabolic markers — fasting glucose, insulin, HbA1c, and lipids — are monitored during treatment to ensure your metabolic health is improving alongside your weight.
- Insurance-aware treatment planning. Medication selection accounts for your insurance coverage. If a GLP-1 is not covered, your clinician identifies the most effective covered alternative and may incorporate metformin or other options to address insulin resistance.
- Integrated lifestyle coaching. Nutrition guidance, exercise recommendations, and sleep optimization are built into your treatment plan — not as generic advice, but as specific strategies designed to improve insulin sensitivity alongside your medication regimen.
Treating weight without addressing insulin resistance is like treating a symptom while ignoring the cause. At PEAK, we treat the whole metabolic picture.
Frequently asked questions
Can insulin resistance be reversed?
Yes. Insulin resistance is not a permanent condition. With weight loss, appropriate medication, and sustained lifestyle changes, many patients significantly improve or fully restore their insulin sensitivity. Research from the Diabetes Prevention Program showed that even 5–10% weight loss can meaningfully reduce insulin resistance and lower the risk of progression to type 2 diabetes. The earlier insulin resistance is identified and treated, the easier it is to reverse.
Does metformin help with weight loss?
Metformin produces modest weight loss — typically 2–3% of body weight. Its primary value for insulin-resistant patients is improving insulin sensitivity and reducing hepatic glucose production, which addresses the metabolic dysfunction that makes weight loss difficult. It is often used alongside dedicated weight loss medications like GLP-1 receptor agonists for a more complete approach.
Are GLP-1 medications better for insulin-resistant patients?
Evidence strongly suggests that GLP-1 receptor agonists are particularly effective for insulin-resistant patients. These medications improve both weight and glucose metabolism simultaneously, breaking the metabolic cycle that makes weight loss so difficult. Tirzepatide (Zepbound), which targets both GLP-1 and GIP receptors, has shown especially strong results in patients with metabolic syndrome and type 2 diabetes in clinical trials like SURMOUNT-2.
How do I know if insulin resistance is causing my weight struggles?
The only way to confirm insulin resistance is through blood testing. Key tests include fasting insulin levels, HOMA-IR calculation, HbA1c, and your triglyceride-to-HDL ratio. Symptoms that suggest insulin resistance include difficulty losing weight despite consistent effort, sugar and carbohydrate cravings, fatigue after meals, and abdominal fat accumulation. If you have any of these symptoms, metabolic screening is worthwhile.
Will I need medication forever for insulin resistance?
Not necessarily. Significant weight loss and sustained lifestyle changes can restore insulin sensitivity to the point where medication is no longer needed. Many patients are able to reduce or discontinue medications after achieving meaningful metabolic improvement. The goal of treatment is not lifelong medication — it is to break the metabolic cycle, achieve a healthier weight, and build the habits that maintain insulin sensitivity long-term. Your clinician will regularly reassess your metabolic markers and adjust your treatment plan accordingly.
Clinical references
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
- Petersen MC, Shulman GI. Mechanisms of insulin resistance in humans and their potential links to inflammation. Physiol Rev. 2018;98(4):2133–2223.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626.
- American Diabetes Association. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1).
